Shanghai Medicilon Inc (688202) fair value: what the stock is really worth
As of Nov 19, 2026: fair value (intrinsic value) of Shanghai Medicilon Inc stock ¥6.82, price ¥67.42, that is 89.9% below the price, quality 50 out of 100. Rating: strongly overvalued. Calculated from audited financials with 10 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Shanghai Medicilon Inc
688202 · SHGFar too expensive (fair value 90% below the price), but solid company and rising price: meets 2 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 20, 2026.
How to read this chart
60‑month range ¥23.83 – ¥394.88 · fair‑value band ¥4.79 – ¥9.60 · the ¥67.42 price screens above the ¥6.82 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 20, 2026.
Every Wednesday you see whether Shanghai Medicilon is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Shanghai Medicilon Inc., a contract research organization, provides drug discovery and development services to pharmaceutical and biotechnology companies in China and internationally. The company operates in Drug Discovery and Pharmaceutical Research, and Preclinical Research segments.
Show moreShow less
It offers medicinal and analytical chemistry; process development; custom and zoom in synthesis; structural, in vitro, and computational biology; protein expression and purification; protein crystallization; and recombinant kinase preparation services, as well as protein target validation, compound activity screening and optimization, raw material and preparation process research, and quality standards and stability research services.
The company also provides process route screening, API production process optimization, drug process research and application, pharmacology services, drug safety evaluation, biological analysis, IND filing, and TCM preclinical trial service solutions, such as pharmaceutical research, pharmacodynamics, pharmacokinetics, and toxicology.
In addition, it offers lipid synthesis, liposome preparation, prescription screening, process optimization and development, quality research, safety evaluation, bioanalysis, registration and declaration, etc.; pre-formulation research, drug analysis, drug stability research, and formulation development; and cytokine and biomarker testing, bioanalysis, and flow cytometry service, as well as engages in the research and development of new drugs.
Further, the company is involved in the molecular drug development business. The company was founded in 2004 and is based in Shanghai, China.
Stock analysis
Shanghai Medicilon Inc (688202) currently trades at ¥67.42, while our model-based Fair Value estimate is ¥6.82, 90% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of ¥7.19 per share, and 0 of the 10 models we run sit above the ¥67.42 price.
Bear case: the Multiples group reads lowest at ¥2.02, and 10 of the 10 models stay below the price. Data coverage for this calculation is low.
Scenario range: ¥4.79 (bear) to ¥9.60 (bull), the price of ¥67.42 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 50/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Shanghai Medicilon Inc reported revenue of 1.2B CNY in FY2025 versus 1.2B CNY in FY2021, a compound −0.1%/yr. Reported net income was −168M CNY in FY2025.
Key figures
Market cap 9.2B CNY (≈ $1.4B) Small · P/S ratio 7.52 · EPS (TTM) ¥−0.7800 · Dividend yield 0.1% · Net margin −7.5% · Return on equity −5.1% · Return on assets (EBIT) 4.7% (5-year average) · Operating margin 10.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 21 out of 100 (low confidence).
What moves the price
The share trades about 42% below its 52-week high and 31% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −90%, 688202 screens richer than that median.
Fair Value models
All 10 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Growth Forecast
Compare Shanghai Medicilon Inc with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- P/S ratio by industry
- EBIT margin by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: Chinese Stocks
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $923.34 | $1,275 | +38% | vs 688202 |
| Vertex Pharmaceuticals Incorporated VRTX | $520.66 | $587.62 | +13% | vs 688202 |
| Samsung Biologics Co 207940 | 1,375,000 KRW | 1,512,500 KRW | +10% | vs 688202 |
| argenx SE ARGX | $942.04 | $908.40 | −4% | vs 688202 |
| CSL Limited CSL | A$197.29 | A$186.49 | −5% | vs 688202 |
| BeOne Medicines AG 6160 | HK$242.60 | HK$152.92 | −37% | vs 688202 |
| Moderna, Inc MRNA | $199.33 | $122.98 | −38% | vs 688202 |
| Revolution Medicines, Inc RVMD | $159.43 | $83.12 | −48% | vs 688202 |
| Celltrion, Inc 068270 | 215,000 KRW | 74,574 KRW | −65% | vs 688202 |
| Royalty Pharma plc RPRX | $67.72 | $19.01 | −72% | vs 688202 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Shanghai Medicilon Inc (688202) overvalued or undervalued?
What is the fair value of 688202?
What is the quality score of 688202?
What is the price target for Shanghai Medicilon Inc (688202)?
What is the Shanghai Medicilon Inc stock forecast for 2026?
What is the revenue of Shanghai Medicilon Inc (688202)?
Does Shanghai Medicilon Inc pay a dividend?
How much is the dividend of Shanghai Medicilon Inc (688202)?
What growth is priced into Shanghai Medicilon Inc (688202)?
What discount rate (WACC) does the fair value of 688202 use?
What is a reverse DCF?
How much growth has Shanghai Medicilon Inc (688202) delivered so far?
How fast is the sector of Shanghai Medicilon Inc (688202) growing?
What is the free cash flow yield of Shanghai Medicilon Inc (688202)?
What is the intrinsic value of Shanghai Medicilon Inc (688202)?
Is Shanghai Medicilon Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 688202?
How much is Shanghai Medicilon Inc worth?
What do the bullish and bearish scenarios say about 688202?
How solid is the balance sheet of Shanghai Medicilon Inc (688202)?
How far is 688202 from its 52-week high?
Which stocks are comparable to Shanghai Medicilon Inc?
Is Shanghai Medicilon Inc stock attractive at the current price?
How is the fair value of 688202 calculated?
Is it still worth investing in stocks now?
What is the share price of Shanghai Medicilon Inc (688202)?
What should I pay attention to with Shanghai Medicilon Inc right now?
Key figures of Shanghai Medicilon Inc
How large is the market capitalisation of Shanghai Medicilon Inc (688202)?
What is the P/S ratio of Shanghai Medicilon Inc (688202)?
What are the earnings per share of Shanghai Medicilon Inc (688202)?
What is the dividend yield of Shanghai Medicilon Inc (688202)?
What is the net margin of Shanghai Medicilon Inc (688202)?
What is the return on equity of Shanghai Medicilon Inc (688202)?
What is the EBIT return on assets of Shanghai Medicilon Inc (688202)?
What is the operating margin of Shanghai Medicilon Inc (688202)?
How fast is revenue growing at Shanghai Medicilon Inc (688202)?
How fast are earnings growing at Shanghai Medicilon Inc (688202)?
How much net debt does Shanghai Medicilon Inc (688202) carry?
Watch Shanghai Medicilon Inc in the live analysis
One click puts Shanghai Medicilon Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.